//]]>

Lentiviral Vectors and Gene Therapy (Record no. 17826)

000 -LEADER
fixed length control field 04828nam a22005415i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140310150240.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120321s2012 sz | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783034804028
978-3-0348-0402-8
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RB155.8
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.895
Edition number 23
264 #1 -
-- Basel :
-- Springer Basel,
-- 2012.
912 ## -
-- ZDB-2-SBL
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Escors, David.
Relator term author.
245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE
Title Lentiviral Vectors and Gene Therapy
Medium [electronic resource] /
Statement of responsibility, etc by David Escors, Karine Breckpot, Frederick Arce, Grazyna Kochan, Holly Stephenson.
300 ## - PHYSICAL DESCRIPTION
Extent IX, 104p. 10 illus., 9 illus. in color.
Other physical details online resource.
440 1# - SERIES STATEMENT/ADDED ENTRY--TITLE
Title SpringerBriefs in Biochemistry and Molecular Biology,
International Standard Serial Number 2211-9353
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note 1 Introduction to gene therapy.- 1.1 The concept of gene therapy -- 1.2 Origins of gene therapy -- 1.3 Gene therapy in the 1970s -- 1.4 Gene therapy in the 1980s -- 1.5 The breakthroughs in gene therapy from the 1990s and 2000s -- 1.6 Current human gene therapy and lentiviral vectors -- 1.7. Concluding remarks.- 2 Development of retroviral and lentiviral vectors.- 2.1 Retrovirus biology -- 2.2 Vectors based on γ -retroviruses -- 2.3 Vectors based on lentiviruses -- 2.4 Summary and conclusions.- 3 Cell and tissue gene targeting with lentiviral vectors -- 3.1 Introduction -- 3.2 Modification of lentivector tropism by pseudotyping (surface targeting) -- 3.3 Transcriptional targeting -- 3.4 Post-transcriptional targeting -- 3.5 Conclusions.-  4 Immunomodulation by genetic modification using lentiviral vectors -- 4.1 Introduction to genetic immunotherapy -- 4.2 Lentivector gene therapy for immunization -- 4.3 Lentivector gene therapy for the treatment of autoimmune disease -- 4.4 Conclusions -- 5 Clinical grade lentiviral vectors.- 5.1 Introduction -- 5.2 Good manufacturing practise guidelines and clinical grade vector preparations -- 5.3 Scaling-up lentivector production for clinical application -- 5.4 Purity of clinical grade lentivectors -- 5.5 Biosafety -- 5.6 Final considerations and conclusions.- 6 Human gene therapy with retrovirus and lentivirus vectors -- 6.1 Introduction -- 6.2 Correction of Severe Combined Immunodeficiency-X1 -- 6.3 Correction of X-linked chronic granulomatous disease -- 6.4 Correction of X-linked adrenoleukodystrophy -- 6.5 Correction of b-thalassaemia -- 6.6 Correction of Wiscott-Aldrich syndrome -- 6.7 Conclusions and final considerations.
520 ## - SUMMARY, ETC.
Summary, etc Gene therapy was conceived during the early and mid part of the 20th century. At first, it was considered a revolutionary biomedical procedure, which could potentially cure any disease for which the molecular bases were understood. Since then, gene therapy has gone through many stages and has evolved from a nearly unrealistic perspective to a real life application. Clinical efficacy in humans was demonstrated at the beginning of this century after its successful application in small-scale clinical trials to cure severe immunodeficiency in children. However, their successes were overshadowed some time later by the occurrence of vector-related leukaemia in a number of treated children. It is in this context that lentiviral vectors have appeared, with improved efficiency and, possibly, increased biosafety. Very recently, the first clinical trials with lentivectors have been carried out with some success. This Brief firstly defines gene therapy, and places lentivectors within this fascinating therapeutic strategy. Then follows a comprehensive description of the development of retroviral and lentiviral vectors and how to specifically target distinct cell types and tissues. The authors also discuss the application of lentivector gene therapy for the treatment of cancer and autoimmune diseases, ending with the application of lentivectors in human gene therapy clinical trials.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Gene therapy.
Topical term or geographic name as entry element Immunology.
Topical term or geographic name as entry element Genetic engineering.
Topical term or geographic name as entry element Oncology.
Topical term or geographic name as entry element Cytology.
Topical term or geographic name as entry element Biomedicine.
Topical term or geographic name as entry element Gene Therapy.
Topical term or geographic name as entry element Immunology.
Topical term or geographic name as entry element Genetic Engineering.
Topical term or geographic name as entry element Cell Biology.
Topical term or geographic name as entry element Oncology.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Breckpot, Karine.
Relator term author.
Personal name Arce, Frederick.
Relator term author.
Personal name Kochan, Grazyna.
Relator term author.
Personal name Stephenson, Holly.
Relator term author.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9783034804011
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-3-0348-0402-8
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Item type E-Book
Copies
Price effective from Permanent location Date last seen Not for loan Date acquired Source of classification or shelving scheme Koha item type Damaged status Lost status Withdrawn status Current location Full call number
2014-04-05AUM Main Library2014-04-05 2014-04-05 E-Book   AUM Main Library615.895
Languages: 
English |
العربية